Printer Friendly Version

Section: Miscellaneous
Number: Z-7
Topic: Electrical Nerve Stimulation
Effective Date: June 5, 2006
Issued Date: June 5, 2006
Date Last Reviewed:

General Policy Guidelines

Indications and Limitations of Coverage

Coverage of electrical nerve stimulation is limited to those stimulators and situations defined within this policy when used to alleviate chronic intractable pain, unless otherwise stated.

CENTRAL NERVOUS SYSTEM

Dorsal Column Stimulator (63650, 63655, 63685)

Dorsal column stimulation is considered experimental/investigational when used as a treatment for conditions other than chronic intractable pain. The medical efficacy for alternate use of this treatment has not been established.

Date Last Reviewed - 09/2005

Deep Brain Neurostimulation (61863, 61864, 61867, 61868, 61885, 61886)

Deep Brain Stimulation (DBS) is eligible to control tremors due to essential tremor (333.1) or Parkinson's Disease (332.0), when medication has failed. Payment will be allowed for DBS using a stimulator implanted on one side of the brain (unilaterally) or on both sides of the brain (bilaterally), and for the subcutaneous implantation of the pulse generator(s) within the patient's chest.

Deep brain stimulation is eligible when used as a treatment for chronic intractable (drug refractory) primary dystonia (333.6), including generalized and/or segmental dystonia, hemidystonia, and cervical dystonia (torticollis) in patients seven years of age or above.

The DBS should be a last resort when all other treatments, including medications, have failed to control the tremors. Further, the patient should receive medical and neurophysiological monitoring before and after the implantation.

Date Last Reviewed - 09/2005

PERIPHERAL NERVOUS SYSTEM

Transcutaneous Electrical Nerve Stimulation (TENS)(64550)
Percutaneous Electrical Nerve Stimulation (PENS)(64555)

Transcutaneous Electrical Nerve Stimulation (TENS) is not an eligible service under the UCR and Fee Schedule programs except as identified in the benefits schedule.

When a covered benefit, both TENS and PENS are reimbursed when used to assess a patient's suitability for continued treatment with an electrical nerve stimulator.

Generally, a physician or physical therapist should be able to determine within a trial period of two months whether the patient is likely to derive a significant therapeutic benefit from the continued use of electrical stimulation. Once this is determined, the patient should use the TENS at home, or if PENS was used, a stimulator should be implanted. Consequently, continued treatments (64550), rather than assessment services, furnished by a physician in his office, by a physical therapist (applicable to TENS only) or outpatient clinic should be denied.

Claims for the TENS or PENS assessment services should be reported under code 95999 with payment equated to the level of reimbursement for an intermediate office visit.

Usually, the physician or physical therapist providing the TENS assessment service will provide the necessary equipment. If the patient rents the stimulator from a supplier during the trial period, payment may be made for the rental of the unit as well as the physician's or physical therapist's service, when a benefit. However, the combined payment may not exceed the amount which would have been payable to the physician or physical therapist alone for the total assessment service.

If the services continue for longer than two months, the claim should be evaluated to determine if the patient's condition is chronic, in which case the TENS would be covered as a prosthetic device.

Date Last Reviewed - 09/2005

Implanted Peripheral Nerve Stimulator (64575, 64590)

The implantation of a peripheral nerve stimulator is eligible when used to alleviate chronic intractable pain.

Date Last Reviewed - 09/2005

Implanted Autonomic Nerve Stimulator (64577)

This procedure is eligible only for the implantation of a phrenic nerve stimulator for treatment of patients with partial or complete respiratory insufficiency (518.5, 518.82). Implantation of an autonomic nerve stimulator other than phrenic is not eligible for payment. In addition, treatment for conditions other than partial or complete respiratory insufficiency is considered experimental/investigational. It is not eligible for reimbursement. The medical efficacy for alternate use of this treatment has not been established. A participating, preferred, or network provider can bill the member for the denied service.

Date Last Reviewed - 09/2005

See Medical Policy Bulletin O-9 for information on the phrenic nerve stimulator device.

Vagus Nerve Stimulator (61885, 61886, 64573)

The implantation of a vagus nerve stimulator for seizure control is eligible only when used as a last resort for patients with epilepsy with partial onset seizures (345.40-345.51). Eligibility is limited to those cases where the seizures cannot be controlled by any other method, i.e., surgery or medication.

The use of vagus nerve stimulation for treatment of refractory depression is considered experimental/investigational.  It is not eligible for payment.  Scientific evidence has not demonstrated the long-term clinical efficacy of VNS and its impact on treatment-resistant depression.  A participating, preferred, or network provider can bill the member for the denied service.

Date Last Reviewed - 03/2006

*****
 
Routine adjustments or maintenance of a nerve stimulator other than a deep brain stimulator, (95970-95975, 95978, 95979) following implantation, and performed during the normal postoperative period, are considered part of the global surgical service.  No additional allowance should be made for this service unless the adjustments are performed after the normal postoperative period.  Adjustments required because of complications are eligible.

Intensive electronic analysis and programming of a deep brain stimulator, may be necessary immediately following implantation to achieve optimal stimulus parameters.  Recognizing these needs, six (6) such programming visits will be covered within 60 days of the surgical implantation of the deep brain stimulator, and once every 30 days thereafter, as necessary.

Claims for the removal of an implanted stimulator should be reported under the appropriate code (63660, 63688, 64585, 64595, 64999). If a second stimulator is implanted (e.g., because of infection or malfunction), payment should be made only for the reimplantation under the appropriate implantation code. No additional allowance should be made for the removal of the first unit.

Use of electrical nerve stimulators and related services other than those listed above, e.g., percutaneous neuromodulation therapy (PNT), or for conditions other than those listed above (e.g., multiple sclerosis, muscular dystrophy, or other motor function disorders), is considered experimental/investigational. It is not eligible for reimbursement. The medical efficacy for alternate use of electrical nerve stimulation has not been established. A participating, preferred, or network provider can bill the member for the denied service.

Nerve stimulators are not covered except under those groups that provide coverage for durable medical equipment (e.g., TENS stimulators - E0720 and E0730) and prosthetic devices (implanted stimulators).

NOTE:
See Medical Policy Bulletin S-131 for guidelines on sacral nerve stimulation.

See Medical Policy Bulletin Y-16 for guidelines on electrical stimulation for wound healing.

See Medical Policy Bulletin E-45 for guidelines on interferential stimulators.

Description

CENTRAL NERVOUS SYSTEM

Dorsal Column Stimulator

Dorsal column stimulation involves the surgical implantation of neurostimulator electrodes within the dura mater (via laminectomy) or the percutaneous insertion of electrodes in the epidural space, often referred to as the PICES (Percutaneous Implantation of Spinal Column Electrical Stimulator) system.

Deep Brain Neurostimulation

Deep brain stimulation (DBS) involves the stereotactic implantation of electrodes in the deep brain (e.g., thalamus and periaqueductal gray matter).

Deep brain stimulation for the control of tremors consists of an electrode(s) implanted into the thalamus, and connected by lead wire(s) under the skin to a pulse generator(s) implanted in the chest. When activated, the device(s) sends a constant stream of tiny electrical pulses to the brain, blocking tremors. To turn the stimulator(s) on or off, the patient passes a handheld magnet over the pulse generator(s).

PERIPHERAL NERVOUS SYSTEM

Transcutaneous Electrical Nerve Stimulation (TENS)

This is a non-invasive technique where the stimulator is attached to the surface of the skin over the peripheral nerve to be stimulated.

Percutaneous Electrical Nerve Stimulation (PENS)

This procedure involves stimulation of the peripheral nerves by a needle electrode inserted through the skin.

Implanted Peripheral Nerve Stimulator

This procedure involves the implantation of electrodes around a selected peripheral nerve.  The stimulating electrode is connected by an insulated lead to a receiver unit which is implanted under the skin at a depth not greater than 1/2 inch. Stimulation is induced by a generator which is connected to an antenna which is attached to the skin surface over the receiver unit.  Sciatic and ulnar nerves are often the sites of such an implant.

Implanted Autonomic Nerve Stimulator

The phrenic nerve stimulator is a type of autonomic nerve stimulator which provides electrical stimulation of the patient's phrenic nerve to contract the diaphragm rhythmically and produce breathing in patients who have hypoventilation.

Vagus Nerve Stimulator

The implantation of a vagus nerve stimulator consists of a generator which is implanted under the collar bone and connected by wire to the vagus nerve in the neck, where it delivers electrical signals to the brain to control seizures. It includes an external programming system which is used by the physician to change stimulation settings. Patients can turn the stimulator on and off with a hand-held magnet by holding it over the stimulator.


NOTE:
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.

Procedure Codes

618636186461867618686188561886
636506365563660636856368864550
645556457364575645776458564590
645956499995970959719597295973
95974959759597895979E0720E0730
L8680L8681L8682L8683L8685L8686
L8687L8688L8689   

Traditional (UCR/Fee Schedule) Guidelines

Refer to General Policy Guidelines

FEP Guidelines

This medical policy may not apply to FEP.  Medical policy is not an authorization, certification, explanation of benefits or a contract.  Benefits are determined by the Federal Employee Program.

Comprehensive / Wraparound / PPO / Major Medical Guidelines

Refer to General Policy Guidelines

Any reference in this bulletin to non-billable services by a network provider may not be applicable to Major Medical.

Managed Care (HMO/POS) Guidelines

Refer to General Policy Guidelines

Publications

PRN References

02/1997, TENS, coverage for
02/1997, PENS, coverage for
02/1998, Deep brain stimulation, coverage for
04/2002, Bilateral deep brain stimulation now covered
04/2003, Age restriction for vagus nerve stimulation removed
02/2004, Deep brain stimulation eligible for treatment of dystonia
02/2004, Percutaneous neuromodulation therapy is investigational
10/2005, Deep brain stimulator programming and analysis coverage revised
08/2006, Vagus nerve stimulation for treatment of refractory depression considered investigational

References

Long-Term Transcutaneous Electrical Nerve Stimulation (TENS) Use: Impact on Medication Utilization and Physical Therapy Costs, Clin J Pain, Vol. 14, Issue 1, 03/1998

Deep Brain Stimulation for Movement Disorders, Neurosurg Clin N Am, Vol. 9, Issue 2, 04/1998

Diaphragm Pacing, Chest Surg Clin N Am, Vol. 8, Issue 2, 05/1998

Vagus Nerve Stimulation Therapy for Partial-Onset Seizures, A Randomized Active-Control Trial, Neurology, Vol. 51, July 1998

Unilateral Thalamic Deep Brain Stimulation for Refractory Essential Tremor and Parkinson's Disease Tremor, Neurology, Vol. 51, Issue 4, 10/1998

Percutaneous Electrical Nerve Stimulation (PENS): A Complementary Therapy for the Management of Pain Secondary to Bony Metastasis, Clin J Pain, Vol. 14, Issue 4, 12/1998

Vagus Nerve Stimulation, Epilepsia, Vol. 39, No. 7, 1998

Percutaneous Electrical Nerve Stimulation for Low Back Pain, A Randomized Crossover Study, Journal of the American Medical Association, Vol. 281, No. 9, 03/1999

The Effects of Epimysial Electrode Location on Phrenic Nerve Recruitment and the Relation Between Tidal Volume and Interpulse Interval, IEEE Trans Rehabil Eng, Vol. 7, Issue 2, 06/1999

Treatment of Neuropathic Pain in a Patient with Diabetic Neuropathy Using Transcutaneous Electrical Nerve Stimulation Applied to the Skin of the Lumbar Region, Physical Therapy, Vol. 79, Issue 8, 08/1999

Neuropsychological and Quality of Life Outcome After Thalamic Stimulation for Essential Tremor, Neurology, Vol. 53, Issue 8, 11/1999

Percutaneous Electrical Nerve Stimulation: An Alternative to TENS in the Management of Sciatica, Pain, Vol. 83, Issue 2, 11/1999

Use of Transcutaneous Electrical Nerve Stimulation in a Young Child with Pain from Open Perineal Lesions, J Pain Symptom Manage, Vol. 18, Issue 5, 11/1999

Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial, Biological Psychiatry, Vol. 58 (5), 09/2005

Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study, Biological Psychiatry, Vol. 58 (5), 09/2005

A One-Year Comparison of Vagus Nerve Stimulation with Treatment as Usual for Treatment-Resistant Depression, Biological Psychiatry, Vol. 58 (5), 09/2005

Two-Year Outcome of Vagus Nerve Stimulation (VNS) for Treatment of Major Depressive Episodes, Journal of Clinical Psychiatry, Vol. 66 (9), 09/2005

View Previous Versions

[Version 011 of Z-7]
[Version 010 of Z-7]
[Version 009 of Z-7]
[Version 008 of Z-7]
[Version 007 of Z-7]
[Version 006 of Z-7]
[Version 005 of Z-7]
[Version 004 of Z-7]
[Version 003 of Z-7]
[Version 002 of Z-7]
[Version 001 of Z-7]

Table Attachment

Text Attachment

Procedure Code Attachment


Glossary





Medical policies do not constitute medical advice, nor are they intended to govern the practice of medicine. They are intended to reflect Highmark's reimbursement and coverage guidelines. Coverage for services may vary for individual members, based on the terms of the benefit contract.

Highmark retains the right to review and update its medical policy guidelines at its sole discretion. These guidelines are the proprietary information of Highmark. Any sale, copying or dissemination of the medical policies is prohibited; however, limited copying of medical policies is permitted for individual use.



back to top